Details of the Drug

General Information of Drug (ID: DMBEX4O)

Drug Name
Methylergonovine
Synonyms
Basofortina; Ergotyl; Metenarin; Methergen; Methergin; Methergine; Methylergobasin; Methylergobasine; Methylergobrevin; Methylergometrin; Methylergometrine; Methylergometrinum; Methylergonovin; Metilergometrina; Metilergometrinio; Partergin; Ryegonovin; Lysergic acid butanolamide; Methylergometrine maleate; Metilergometrina [DCIT]; ME 277; Ergotyl (TN); Methergine (TN); Methylergometrine (INN); Methylergometrine [INN:BAN]; Methylergometrinum [INN-Latin]; Metilergometrinio [INN-Spanish]; Spametrin-M; D-Lysergic acid-dl-hydroxybutylamide-2; N-(alpha-(Hydroxymethyl)propyl)-D-lysergamide; D-Lysergic acid-(+)-butanolamide-(2); (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-6-methyl-9,10-didehydroergoline-8-carboxamide; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-6-methylergoline-8-carboxamide; 9,10-Didehydro-N-(alpha-(hydroxymethyl)propyl)-6-methyl-ergoline-8-beta-carboxamide
Indication
Disease Entry ICD 11 Status REF
Spontaneous abortion JA00.0 Approved [1]
Therapeutic Class
Oxytocics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 339.4
Topological Polar Surface Area (xlogp) 2.3
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 3.39 hours [2]
Metabolism
The drug is metabolized via the hepatic [3]
Vd
The volume of distribution (Vd) of drug is 56.1 +/- 0 L [4]
Chemical Identifiers
Formula
C20H25N3O2
IUPAC Name
(6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
Canonical SMILES
CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
InChI
InChI=1S/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25)/t13-,14+,18-/m1/s1
InChIKey
UNBRKDKAWYKMIV-QWQRMKEZSA-N
Cross-matching ID
PubChem CID
8226
ChEBI ID
CHEBI:92607
CAS Number
113-42-8
DrugBank ID
DB00353
TTD ID
D05AHE
VARIDT ID
DR00997
INTEDE ID
DR1052
ACDINA ID
D00418

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D1 receptor (D1R) TTZFYLI DRD1_HUMAN Antagonist [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Spontaneous abortion
ICD Disease Classification JA00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D1 receptor (D1R) DTT DRD1 8.99E-01 -0.06 -0.3
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.76E-01 1.26E-01 8.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Methylergonovine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Methylergonovine caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [26]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Methylergonovine caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [26]
Arn-509 DMT81LZ Moderate Increased metabolism of Methylergonovine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [26]
Mitotane DMU1GX0 Moderate Increased metabolism of Methylergonovine caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [26]
Epinephrine DM3KJBC Major Additive hypertensive effects by the combination of Methylergonovine and Epinephrine. Allergic/hypersensitivity disorder [4A80-4A8Z] [27]
Nifedipine DMSVOZT Moderate Decreased metabolism of Methylergonovine caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [28]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Methylergonovine caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [26]
Voriconazole DMAOL2S Major Decreased metabolism of Methylergonovine caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [29]
Posaconazole DMUL5EW Major Decreased metabolism of Methylergonovine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [29]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Methylergonovine caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [28]
Ephedrine DMMV0KW Major Additive hypertensive effects by the combination of Methylergonovine and Ephedrine. Asthma [CA23] [27]
Oritavancin DM28D05 Moderate Increased metabolism of Methylergonovine caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [26]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Methylergonovine caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [28]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Methylergonovine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [28]
Clarithromycin DM4M1SG Major Decreased metabolism of Methylergonovine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [30]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Methylergonovine caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [28]
Troleandomycin DMUZNIG Major Decreased metabolism of Methylergonovine caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [30]
Telithromycin DMZ4P3A Major Decreased metabolism of Methylergonovine caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [31]
Erdafitinib DMI782S Moderate Increased metabolism of Methylergonovine caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [32]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Methylergonovine caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [26]
Tucatinib DMBESUA Major Decreased metabolism of Methylergonovine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [30]
Pseudoephedrine DMIVJ0D Major Additive hypertensive effects by the combination of Methylergonovine and Pseudoephedrine. Breathing abnormality [MD11] [27]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of Methylergonovine caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [28]
Secobarbital DM14RF5 Moderate Increased metabolism of Methylergonovine caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [26]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Methylergonovine caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [26]
Mifepristone DMGZQEF Major Decreased metabolism of Methylergonovine caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [33]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Methylergonovine caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [28]
Aminoglutethimide DMWFHMZ Moderate Increased metabolism of Methylergonovine caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [26]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Methylergonovine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [26]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Methylergonovine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [28]
MK-8228 DMOB58Q Major Decreased metabolism of Methylergonovine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [30]
Aprepitant DM053KT Moderate Decreased metabolism of Methylergonovine caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [28]
Nefazodone DM4ZS8M Major Decreased metabolism of Methylergonovine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [34]
Griseofulvin DMK54YG Moderate Increased metabolism of Methylergonovine caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [26]
LEVONORDEFRIN DMWDJ0H Major Additive hypertensive effects by the combination of Methylergonovine and LEVONORDEFRIN. Discovery agent [N.A.] [27]
Primidone DM0WX6I Moderate Increased metabolism of Methylergonovine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Felbamate DM1V5ZS Moderate Increased metabolism of Methylergonovine caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Methylergonovine caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Cenobamate DMGOVHA Moderate Increased metabolism of Methylergonovine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Methylergonovine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Rufinamide DMWE60C Moderate Increased metabolism of Methylergonovine caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Phenobarbital DMXZOCG Moderate Increased metabolism of Methylergonovine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Carbamazepine DMZOLBI Moderate Increased metabolism of Methylergonovine caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Methylergonovine caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Mephentermine DMFJH5Q Major Additive hypertensive effects by the combination of Methylergonovine and Mephentermine. Essential hypertension [BA00] [27]
Oxymetazoline DM8ZXT6 Major Additive hypertensive effects by the combination of Methylergonovine and Oxymetazoline. Eyelid inflammatory disorder [9A02] [27]
Phenylephrine DMZHUO5 Major Additive hypertensive effects by the combination of Methylergonovine and Phenylephrine. Faecal incontinence [ME07] [27]
Tazemetostat DMWP1BH Moderate Increased metabolism of Methylergonovine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [26]
Itraconazole DMCR1MV Major Decreased metabolism of Methylergonovine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [29]
Miconazole DMPMYE8 Moderate Decreased metabolism of Methylergonovine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [35]
Ketoconazole DMPZI3Q Major Decreased metabolism of Methylergonovine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [29]
Cimetidine DMH61ZB Moderate Decreased metabolism of Methylergonovine caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [28]
Dipivefrin DMH5W0G Major Additive hypertensive effects by the combination of Methylergonovine and Dipivefrin. Glaucoma [9C61] [27]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Methylergonovine caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [26]
Boceprevir DMBSHMF Major Decreased metabolism of Methylergonovine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [36]
Telaprevir DMMRV29 Major Decreased metabolism of Methylergonovine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [36]
Tetrahydrozoline DMT57WC Major Additive hypertensive effects by the combination of Methylergonovine and Tetrahydrozoline. Herpes simplex infection [1F00] [27]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Methylergonovine caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [28]
Rifampin DMA8J1G Moderate Increased metabolism of Methylergonovine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [26]
Rifapentine DMCHV4I Moderate Increased metabolism of Methylergonovine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [26]
MK-1439 DM215WE Moderate Increased metabolism of Methylergonovine caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [26]
Delavirdine DM3NF5G Major Decreased metabolism of Methylergonovine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Methylergonovine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Cobicistat DM6L4H2 Major Decreased metabolism of Methylergonovine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [30]
Efavirenz DMC0GSJ Major Decreased metabolism of Methylergonovine caused by Efavirenz mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Saquinavir DMG814N Major Decreased metabolism of Methylergonovine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Etravirine DMGV8QU Moderate Increased metabolism of Methylergonovine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [26]
Amprenavir DMLMXE0 Major Decreased metabolism of Methylergonovine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Darunavir DMN3GCH Major Decreased metabolism of Methylergonovine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Atazanavir DMSYRBX Major Decreased metabolism of Methylergonovine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Ritonavir DMU764S Major Decreased metabolism of Methylergonovine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Levamlodipine DM92S6N Moderate Decreased metabolism of Methylergonovine caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [28]
Verapamil DMA7PEW Moderate Decreased metabolism of Methylergonovine caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [28]
Amlodipine DMBDAZV Moderate Decreased metabolism of Methylergonovine caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [28]
Methoxamine DMF5XQH Major Additive hypertensive effects by the combination of Methylergonovine and Methoxamine. Hypertension [BA00-BA04] [27]
Conivaptan DM1V329 Major Decreased metabolism of Methylergonovine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [39]
Metaraminol DMWIX23 Major Additive hypertensive effects by the combination of Methylergonovine and Metaraminol. Hypotension [BA20-BA21] [27]
Lesinurad DMUR64T Moderate Increased metabolism of Methylergonovine caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [26]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Methylergonovine caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [28]
Amobarbital DM0GQ8N Moderate Increased metabolism of Methylergonovine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [26]
Naphazoline DMJFZDL Major Additive hypertensive effects by the combination of Methylergonovine and Naphazoline. Itching [1F28-1G07] [27]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Methylergonovine caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [26]
Crizotinib DM4F29C Moderate Decreased metabolism of Methylergonovine caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [28]
Brigatinib DM7W94S Moderate Increased metabolism of Methylergonovine caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [26]
Ceritinib DMB920Z Major Decreased metabolism of Methylergonovine caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [30]
PF-06463922 DMKM7EW Moderate Increased metabolism of Methylergonovine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [26]
Osimertinib DMRJLAT Moderate Increased metabolism of Methylergonovine caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [40]
Selpercatinib DMZR15V Moderate Decreased metabolism of Methylergonovine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [28]
Idelalisib DM602WT Major Decreased metabolism of Methylergonovine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [30]
IPI-145 DMWA24P Moderate Decreased metabolism of Methylergonovine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [28]
Vemurafenib DM62UG5 Moderate Increased metabolism of Methylergonovine caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [26]
LGX818 DMNQXV8 Moderate Increased metabolism of Methylergonovine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [41]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Methylergonovine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [40]
Danazol DML8KTN Moderate Decreased metabolism of Methylergonovine caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [28]
Exjade DMHPRWG Moderate Increased metabolism of Methylergonovine caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [26]
Rifabutin DM1YBHK Moderate Increased metabolism of Methylergonovine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [26]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Methylergonovine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [28]
Nilotinib DM7HXWT Moderate Decreased metabolism of Methylergonovine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [28]
Imatinib DM7RJXL Moderate Decreased metabolism of Methylergonovine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [28]
Dasatinib DMJV2EK Moderate Decreased metabolism of Methylergonovine caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [28]
Modafinil DMYILBE Moderate Increased metabolism of Methylergonovine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [26]
Netupitant DMEKAYI Moderate Decreased metabolism of Methylergonovine caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [28]
Entrectinib DMMPTLH Moderate Decreased metabolism of Methylergonovine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [28]
Propylhexedrine DMTBW2O Major Additive hypertensive effects by the combination of Methylergonovine and Propylhexedrine. Obesity [5B80-5B81] [27]
Phenylpropanolamine DMTFK3O Major Additive hypertensive effects by the combination of Methylergonovine and Phenylpropanolamine. Obesity [5B80-5B81] [27]
Olaparib DM8QB1D Moderate Decreased metabolism of Methylergonovine caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [26]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Methylergonovine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [28]
Dopamine DMPGUCF Major Additive hypertensive effects by the combination of Methylergonovine and Dopamine. Parkinsonism [8A00] [27]
Abametapir DM2RX0I Moderate Decreased metabolism of Methylergonovine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [42]
Lanreotide acetate DMG6ZU4 Moderate Decreased metabolism of Methylergonovine caused by Lanreotide acetate mediated inhibition of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [28]
Lefamulin DME6G97 Moderate Decreased metabolism of Methylergonovine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [43]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Methylergonovine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [30]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Methylergonovine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [28]
Enzalutamide DMGL19D Moderate Increased metabolism of Methylergonovine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [26]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Methylergonovine caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [28]
Bosentan DMIOGBU Moderate Increased metabolism of Methylergonovine caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [26]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Methylergonovine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [44]
Dexamethasone DMMWZET Moderate Increased metabolism of Methylergonovine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [26]
Nafcillin DMN9RPO Moderate Increased metabolism of Methylergonovine caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [26]
Norepinephrine DMOUC09 Major Additive hypertensive effects by the combination of Methylergonovine and Norepinephrine. Sepsis [1G40-1G41] [27]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Methylergonovine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [28]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Methylergonovine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [26]
Larotrectinib DM26CQR Moderate Decreased metabolism of Methylergonovine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [28]
Armodafinil DMGB035 Moderate Increased metabolism of Methylergonovine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
LEE011 DMMX75K Moderate Decreased metabolism of Methylergonovine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [28]
Pitolisant DM8RFNJ Moderate Increased metabolism of Methylergonovine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [26]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Methylergonovine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [45]
Brilinta DMBR01X Moderate Decreased metabolism of Methylergonovine caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [40]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Methylergonovine and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [44]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Methylergonovine and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [44]
Elagolix DMB2C0E Moderate Increased metabolism of Methylergonovine caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [26]
Xylometazoline DMKV32D Major Additive hypertensive effects by the combination of Methylergonovine and Xylometazoline. Vasomotor/allergic rhinitis [CA08] [27]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Methylergonovine caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [28]
⏷ Show the Full List of 133 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
D-tartaric acid E00416 439655 Acidulant; Complexing agent; Flavoring agent
FD&C blue no. 1 E00263 19700 Colorant
Maleic acid E00418 444266 Acidulant; Buffering agent
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Propylparaben sodium E00567 23679044 Antimicrobial preservative
Sodium benzoate E00432 517055 Antimicrobial preservative; lubricant
Sodium methylparaben E00543 23663626 Antimicrobial preservative
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Gelatin E00630 Not Available Other agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Lithol rubin BCA E00607 135423095 Colorant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Sodium hydroxide E00234 14798 Alkalizing agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Tartaric acid E00029 875 Acidulant; Complexing agent; Flavoring agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Methylergonovine 0.2 mg tablet 0.2 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5 Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
6 Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9.
7 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
8 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
9 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
10 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
11 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
12 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
13 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
14 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
15 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
16 Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
18 Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
19 Clinical pipeline report, company report or official report of Lundbeck.
20 A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
21 Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
22 trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
23 Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
24 The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol. 1988 Nov 1;156(2):197-206.
25 Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats. Eur J Pharmacol. 2005 Mar 7;510(1-2):121-6.
26 Cerner Multum, Inc. "Australian Product Information.".
27 Barthel W, Glusa E, Koth W "Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ." Int J Clin Pharmacol Ther Toxicol 25 (1987): 63-9. [PMID: 2881898]
28 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
29 Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7. [PMID: 10616689]
30 Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7. [PMID: 314074]
31 Horowitz RS, Dart RC, Gomez HF "Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction." Arch Intern Med 156 (1996): 456-8. [PMID: 8607732]
32 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
33 He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
34 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
35 Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207. [PMID: 9145904]
36 Baldwin ZK, Ceraldi CC "Ergotism associated with HIV antiviral protease inhibitor therapy." J Vasc Surg 37 (2003): 676-8. [PMID: 12618710]
37 Product Information. Cafergot (caffeine-ergotamine). Novartis Pharmaceuticals, East Hanover, NJ.
38 Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
39 Bird PA, Sturgess AD "Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction." Aust N Z J Med 30 (2000): 635-6. [PMID: 11108077]
40 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
41 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
42 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
43 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
44 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
45 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.